Clinical trials: Pigment Deposition
Sunscreening Agents
Sun Protection Factor Assay (317/2016)
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02995018)
- Testing
- BAY987521, SPF Control
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Open-angle Glaucoma, Ocular Hypertension
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT00372827
- Testing
- Brinzolamide 1% added to Travoprost 0.004%
- Where
- Germany
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Retinitis Pigmentosa (RP)
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
The purpose of this study is: To evaluate whether 7-day treatment with oral QLT091001 can improve visual function in RP subjects with an autosomal dominant mutation in RPE65.
- Trial name
- NCT01543906
- Testing
- QLT091001
- Where
- 2 sites in Canada, Ireland
- Volunteers
- 5 people
- Sponsor
- QLT Inc.
Sunscreening Agent
Sun Protection Factor Assay
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02822313)
- Testing
- Coppertone (BAY987518)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bayer
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
The purpose of this study is: To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 To…
- Trial name
- NCT01521793
- Testing
- QLT091001
- Where
- 6 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- QLT Inc.
Pigment; Lesion, Lesion; Vascular
Image Data Collection of Tanned Skin During Phototherapy Treatment Using a Multi-spectral Camera
This is a prospective, observational, single-center, image collection study. Any patient who arrived at the phototherapy clinic for the first time, regardless of this study, and is prescribed a total of 30 treatments can be…
- Trial name
- NCT05692544
- Testing
- Phototherapy treatment
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to DUOTRAV® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having…
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT01327599
- Testing
- Travoprost 0.004%+Timolol 0.5% ophthalmic solution
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Sunscreening Agent
Sun Protection Factor - Assay
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02779842)
- Testing
- Coppertone (BAY 987517)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Sunscreening Agents
Sun Protection Factor Assay
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02815241)
- Testing
- BAY987517
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bayer
Sunscreening Agents
Sun Protection Factor Assay (SPF Assay 199/2016)
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- NCT02930746
- Testing
- BAY987516
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Bayer
Macular Pigment Optical Density
"Visiobiane Anti-age" Effects on Vision Parameters
The purpose of this study is to determine the benefits of "Visiobiane Anti-age" dietary supplement on macular pigment optical density, contrast sensibility and visual acuity.
- Trial name
- NCT00449917
- Testing
- lutein, DHA, vitamins
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- PiLeJe
Lentigo, Hyperpigmentation
Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy
Pierre Fabre Dermo-Cosmétique has commercialized a cosmetic product (D-pigment rich texture) for treatment of hyperpigmentation.
- Trial name
- NCT03457246
- Testing
- D-Pigment rich texture, Hydrance optimale riche
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there…
- Trial name
- NCT01682382
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Sunscreening Agents
18611 - Sun Protection Factor Assay
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- NCT02760563
- Testing
- BAY 987517
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bayer
Geographic Atrophy, Stargardt Disease
Phase 1 Study of C.001 in Retinal Degeneration
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.
- Conditions
- Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
- Trial name
- NCT07594236
- Testing
- Injection
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellio Therapeutics Inc
Sunscreening Agents
Sun Protection Factor Assay (SPF Assay 205/2016)
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- NCT02936557
- Testing
- BAY987521
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Bayer
Sunscreening Agent
Sun Protection Factor Assay
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02803099)
- Testing
- Coppertone (BAY 987517)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bayer
Sunscreening Agents
Sun Protection Factor Assay (316/2016)
To evaluate the Sun Protection Factor efficacy on human skin.
- Trial name
- SPF Assay (NCT02994992)
- Testing
- BAY 987516, SPF Control
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer